Intelligence Feed event · Equity · 2026-09-13

    Eli Lilly Immunology Revenue Hits $2.6B in H1 2026, Growing 9% YoY

    Question

    Eli Lilly Immunology Revenue Hits $2.6B in H1 2026, Growing 9% YoY

    Direct answer

    Eli Lilly's Immunology business generated $2.6 billion in the first half of 2026, advancing 9% year-over-year to account for 6.1% of consolidated net sales. The segment is anchored by mature asset Taltz while scaling newer therapies Ebglyss and Omvoh. The franchise is reinforced by pipeline bolt-ons including DICE Therapeutics, Morphic Holding, and Merida. This non-incretin growth pillar broadens Lilly's commercial profile beyond metabolic treatments.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-13
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Eli Lilly Immunology Revenue Hits $2.6B in H1 2026, Growing 9% YoY”, revision 1, evidence through 2026-09-13. https://marketontology.com/market-events/2026-09-13/eli-lilly-immunology-revenue-hits-2-6b-in-h1-2026-growing-9-yoy-66afb9

    EQUITY
    Eli Lilly Immunology Revenue Hits $2.6B in H1 2026, Growing 9% YoY
    Eli Lilly's Immunology business generated $2.6 billion in the first half of 2026, advancing 9% year-over-year to account for 6.1% of consolidated net sales. The segment is anchored by mature asset Taltz while scaling newer therapies Ebglyss and Omvoh. The franchise is reinforced by pipeline bolt-ons including DICE Therapeutics, Morphic Holding, and Merida. This non-incretin growth pillar broadens Lilly's commercial profile beyond metabolic treatments.
    LLYABBV
    Impact
    64
    SEP 13
    SIG
    85%
    LLYABBV
    Eli Lilly Immunology Revenue Hits $2.6B in H1 2026, Growing 9% YoY
    Eli Lilly's Immunology business generated $2.6 billion in the first half of 2026, advancing 9% year-over-year to account for 6.1% of consolidated net sales. The segment is anchored by mature asset Taltz while scaling newer therapies Ebglyss and Omvoh. The franchise is reinforced by pipeline bolt-ons including DICE Therapeutics, Morphic Holding, and Merida. This non-incretin growth pillar broadens Lilly's commercial profile beyond metabolic treatments.
    → Immunology revenue growth to $2.6 billion diversifies Eli Lilly's top-line cash flows away from core incretin franchise concentration.
    Impact
    Eli Lilly's Immunology business generated $2.6 billion in the first half of 2026, advancing 9% year-over-year to account for 6.1% of consolidated net sales. The segment is anchored by mature asset Taltz while scaling newer therapies Ebglyss and Omvoh. The franchise is reinforced by pipeline bolt-ons including DICE Therapeutics, Morphic Holding, and Merida. This non-incretin growth pillar broadens Lilly's commercial profile beyond metabolic treatments.
    Affected
    LLYABBV
    Transmission
    Immunology revenue growth to $2.6 billion diversifies Eli Lilly's top-line cash flows away from core incretin franchise concentration.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYnon-incretin revenue diversification supporting gross margin stabilityUp1-4wImmunology unit posted $2.6 billion in H1 2026 sales, up 9% YoY.
    ABBVcompetitive market share contest in immunology and dermatologyWatch1-3mExpansion of Ebglyss and Omvoh challenges legacy immunology market share.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month